Jump to content

TissueLabs

Add links
From Wikipedia, the free encyclopedia
TissueLabs SA
TypePrivate
IndustryBioengineering
Founded2019
Founder
HeadquartersBellinzona, Switzerland
Key people
  • Gabriel Liguori (CEO)
  • Emerson Moretto (CTO)
  • Felipe Brito (CFO)
Products3D Bioprinters and Biomaterials
Number of employees
11-50
Websitehttps://www.tissuelabs.com/

TissueLabs is a Swiss biotechnology company based in Bellinzona.[1] The company focuses on tissue engineering and biofabrication and develops 3D bioprinters and tissue-specific biomaterials for use in laboratory research applications including drug testing, disease modeling and cell culture.[2][3][4]

History

[edit]

TissueLabs was founded in January 2019 in Brazil by Gabriel Liguori and Emerson Moretto.[5][6] The company originated in the IPEN-Cietec incubator at the University of São Paulo and raised approximately $1.6 million in seed funding during its initial phase of development.[1] In 2021, the company relocated its headquarters to Switzerland, initially based in Manno before moving to Bellinzona.[7]

Early development

[edit]

During its early development, TissueLabs focused on laboratory tools for tissue engineering research.

In 2019, the company introduced MatriXpec, a line of tissue-specific hydrogels derived from decellularized extracellular matrix, developed for use in three-dimensional cell culture and bioprinting.[8] By 2020, formulations had been developed for tissue types including myocardium, lung, liver, kidney, skin, and cartilage.[9][10]

In 2020, TissueLabs introduced TissueStart, an extrusion-based 3D bioprinter designed for academic and laboratory use.[11]

In early 2020, during the COVID-19 pandemic, it developed MatriWell, an in vitro system combining a cell culture insert with lung-derived hydrogels to model aspects of lung epithelium. The system was made for research use in studies of SARS-CoV-2 infection in pulmonary cells.[12] MatriWell was also used in a 2023 peer-reviewed research examining three-dimensional models for respiratory disease investigation.[13]

Growth

[edit]

In 2021, TissueLabs introduced TissueRay, an MSLA-based 3D bioprinter. The system was presented at the 6th Tissue Engineering and Regenerative Medicine International Society (TERMIS) World Congress.[14][15]

In 2023, the company closed a pre-seed financing round of $800,000, led by Mergus Ventures, with participation from MIT Angels and others.[16] The funds supported the establishment of a new biofabrication facility in Bellinzona, which began operations in early 2024.[17] Initially based in Manno, the relocation to Bellinzona was related to being closer to European biotech and research networks.[1]

In 2024, TissueLabs was selected to participate in the Venture Leaders Biotech program, a Swiss initiative supporting early-stage biotechnology companies.[18]

In 2025, TissueLabs introduced TissuePro, a 3D bioprinter with five independent extrusion heads designed for more complex tissue engineering applications.[19][20][3] It was also included in the Top 100 Startups to Watch list published by Pequenas Empresas & Grandes Negócios (PEGN) that year.[21]

Research

[edit]

According to statements by the company and its founder, TissueLabs is pursuing long-term research into the development of a bioartificial heart using patient-derived cells.[22] In a 2021 interview, Liguori stated that clinical trials for such a device could require an additional 10–15 years of research and development.[6][3][23]

See also

[edit]

References

[edit]
  1. 1 2 3 Listek, Vanesa (2021-10-16). "Bioprinting Startup TissueLabs Moves HQ from Brazil to Switzerland". 3DPrint.com. Retrieved 2026-04-01.
  2. ↑ Listek, Vanesa (2021-12-02). "New Masked SLA Bioprinter Revealed by TissueLabs". 3DPrint.com. Retrieved 2026-04-01.
  3. 1 2 3 Abirascid, Emil (2026-04-27). "From patient to pioneer: the entrepreneur revolutionising organ transplants". Startupbusiness.it. Retrieved 2026-05-15.
  4. ↑ Andrion, Roseli. "Brazilian startup aims to manufacture custom-made human organs". AGÊNCIA FAPESP. Retrieved 2026-09-29.
  5. ↑ "Gabriel Liguori". MIT Technology Review Innovators Under 35. Retrieved 2026-04-01.
  6. 1 2 Riga, Matheus (2021-07-01). "Healthtech brasileira está no caminho para viabilizar impressão em 3D de órgãos humanos". Forbes Brasil (in Brazilian Portuguese). Retrieved 2026-04-01.
  7. ↑ Listek, Vanesa (2021-02-11). "Bioprinting Startup TissueLabs Moves HQ from Brazil to Switzerland". 3DPrint.com | Additive Manufacturing Business. Retrieved 2026-09-25.
  8. ↑ Josino, Raphaella; Stimamiglio, Marco Augusto (2023). "Bioactive decellularized extracellular matrix-based hydrogel supports human adipose tissue-derived stem cell maintenance and fibrocartilage phenotype". Frontiers in Bioengineering and Biotechnology. 11 1304030. doi:10.3389/fbioe.2023.1304030. ISSN 2296-4185. PMC 10800544. PMID 38260748.
  9. ↑ "Estas empresas vão mudar a forma como cuidamos da nossa saúde". Época Negócios (in Brazilian Portuguese). 2022-08-24. Retrieved 2026-04-01.
  10. ↑ Dos Santos, Jeniffer Farias; Freitas-Marchi, Bruna Letícia; Reigado, Gustavo Roncoli; de Assis, Silvia Romano; Maria Engler, Silvya Stuchi; Chambergo Alcalde, Felipe Santiago; Nunes, Viviane Abreu (2022). "Mesenchymal stem cells express epidermal markers in an in vitro reconstructed human skin model". Frontiers in Cell and Developmental Biology. 10 1012637. doi:10.3389/fcell.2022.1012637. ISSN 2296-634X. PMC 9878690. PMID 36712971.
  11. ↑ Duran, Paloma (2025-06-12). "TissueLabs Scales Bioprinting with Launch of TissuePro: Technical Specifications". 3D Printing Industry. Retrieved 2026-09-25.
  12. ↑ "TissueLabs: New 3D Printed Platform Free to Researchers Studying COVID-19". 3DPrint.com. 2020. Retrieved 2026-04-01.
  13. ↑ Seixas, Maria Luiza; Bartolomeo, Cynthia Silva; Lemes, Robertha; Nicoliche, Tiago; Okuda, Liria Hiromi; Martins, Leonardo; Ureshino, Rodrigo; Prado, Carla Maximo; Liguori, Tácia Tavares Aquinas; Liguori, Gabriel Romero; Stilhano, Roberta Sessa (2023-09-01). "Disruptive 3D in vitro models for respiratory disease investigation: A state-of-the-art approach focused on SARS-CoV-2 infection". Biomaterials and Biosystems. 11 100082. doi:10.1016/j.bbiosy.2023.100082. ISSN 2666-5344. PMC 10391659. PMID 37534107.
  14. ↑ Sher, Davide (2021-11-15). "First commercial MSLA 3D bioprinter TissueRay hits market". VoxelMatters - The heart of additive manufacturing. Retrieved 2026-09-28.
  15. ↑ 3Druck.com (2021-11-22). "The first commercial MSLA 3D bioprinter TissueRay comes onto the market". 3Druck.com - The Independent AM Magazine. Retrieved 2026-09-28.{{cite web}}: CS1 maint: numeric names: authors list (link)
  16. ↑ "TissueLabs secures $800 k and unveils new biofabrication hub in Bellinzona". www.startupticker.ch. Archived from the original on 2025-08-09. Retrieved 2026-06-05.
  17. ↑ "TissueLabs begins biofabrication activities in Bellinzona". Greater Zurich Area. 2024-03-25. Retrieved 2026-04-01.
  18. ↑ "TissueLabs: The Venture Leader Biotech fabricating lab-grown tissues for research and therapeutic applications". www.venture-leaders.ch. Retrieved 2026-09-25.
  19. ↑ Duran, Paloma (2025-06-12). "TissueLabs Scales Bioprinting with Launch of TissuePro: Technical Specifications". 3D Printing Industry. Retrieved 2026-04-01.
  20. ↑ "TissueLabs launches new TissuePro extrusion-based bioprinter". VoxelMatters. 2025-06-02. Retrieved 2026-04-01.
  21. ↑ "Conheça as 100 Startups to Watch 2025". Pequenas Empresas & Grandes Negócios. 2025. Retrieved 2026-04-01.
  22. ↑ Liguori, Gabriel R. (2025). "The Bioartificial Heart: Our Mission to Mars". Brazilian Journal of Cardiovascular Surgery. 40 (1): e20250044. doi:10.21470/1678-9741-2025-0044. PMC 11927143. PMID 40105295.
  23. ↑ "Rate limit reached". scholar.archive.org. Retrieved 2026-06-05.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=TissueLabs&oldid=1379008583"